ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) has earned a consensus rating of “Buy” from the five research firms that are covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in […]